Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,241.20
(
-1.16%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
107.05
(
-1.40%
)
Bitcoin
67,457.99
(
1.13%
)
News Focus
News Focus
Post# of 257314
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 143852

Thursday, 06/14/2012 11:07:13 AM

Thursday, June 14, 2012 11:07:13 AM

Post# of 257314
As noted in #msg-76571926, the technical problems of co-formulating Lucentis and Fovista may be more consequential than the legal/anti-competitive issues. I’m not aware of any cases of co-formulation involving a biologic (in this instance, a biologic and an aptamer). Do you know of any?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today